Eleven Biotherapeutics, Inc. EBIO
— —
At closeJun 28, 2019, 6:07 PM EDT
Day range unavailable
52-week range unavailable
No chart data for this range yet.
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 9, 2018 | Laidlaw & Co. | init | — | Buy |
| Mar 19, 2018 | H.C. Wainwright | init | — | Buy |
| Jan 18, 2016 | Leerink Swann | down | — | Market Perform |
| Mar 2, 2014 | Citigroup | init | — | Buy |
| Mar 2, 2014 | Cowen & Co. | init | — | Outperform |
| Mar 2, 2014 | Citigroup | init | — | Buy |
News
40 Stocks Moving In Wednesday's Mid-Day Session 
Eleven Biotherapeutics Reports First Quarter Financial Results and
Pipeline Updates 
Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results
on November 14, 2017 
Eleven Biotherapeutics to Report Second Quarter 2017 Financial
Results on Monday, August 14, 2017 
Eleven Biotherapeutics to Report First Quarter 2017 Financial Results
on Thursday, May 4, 2017 
Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2016
Financial Results on Friday, March 24, 2017 
Eleven Biotherapeutics to Report Third Quarter 2016 Financial Results
on November 14, 2016 
Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted
Protein Therapeutics Oncology Company 
Eleven Biotherapeutics to Report Third Quarter 2015 Financial Results
on November 4, 2015 
Morning Market Gainers
Your note
Sign in to keep a note on EBIO — it syncs with the Stock Master app.